Megace (Megestrol Acetate)

Megestrol acetate is a synthetic progestogen that activates progesterone receptors, producing anti‑estrogenic effects that inhibit growth of hormone‑dependent cancer cells. It also acts on the hypothalamus to increase appetite‑stimulating neuropeptides, leading to greater food intake and weight gain.

The dosage of Megace is individualized and set by the prescribing clinician based on the patient’s condition, weight, and response. Physicians determine the appropriate strength and treatment duration, and patients should follow the prescriber’s instructions without self‑adjusting the dose.

The safety of Megace in pregnancy and lactation has not been established, and the pregnancy category is listed as unknown. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and a healthcare professional must evaluate each case.

To order Megace, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Megace differs from other appetite stimulants such as dronabinol or mirtazapine by acting as a synthetic progestogen with both appetite‑enhancing and anti‑estrogenic properties. While dronabinol works via cannabinoid receptors and mirtazapine via antihistaminic effects, Megace also offers antineoplastic activity useful in certain cancers.

Megace tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light, and store out of reach of children. No refrigeration is required for this oral formulation.

Megace is taken orally as a tablet, with or without food, according to the prescriber’s directions. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed by a healthcare professional.

Serious risks associated with Megace include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, adrenal suppression leading to cortisol deficiency, significant hyperglycemia, and severe allergic reactions like rash, angioedema or anaphylaxis. Patients should seek immediate medical attention if these occur.

Megace is contraindicated in patients with known hypersensitivity to megestrol acetate or any excipients, those with active thromboembolic disease, uncontrolled diabetes, or severe liver impairment. Caution is also advised for individuals receiving systemic corticosteroids or other hormonal therapies, and it should be avoided in pregnancy unless clearly needed.